As hospitalizations and deaths from Covid-19 rise, governments are grappling with whether to prioritize getting a first shot of vaccine into as many arms as possible, or to take a slower approach that reserves some of the limited supply to deliver a second dose at the optimal interval to attain maximum protection. Some governments seem willing to accept the tradeoff of lower immunity to inoculate more people. Some scientists have cautioned that untested timing regimens have the potential to undermine confidence in vaccines and, even worse, facilitate the emergence of dangerous new variants.<\/p>\n
Covid-19 vaccines made by Moderna Inc., Pfizer Inc.-BioNTech SE, and AstraZeneca Plc are administered in two doses. The recommended timing of the second dose varies depending on the vaccine, and is based on clinical trial data regulators used in their review process. In studies, the second Pfizer-BioNTech dose was given 21 days after the initial shot; Moderna\u2019s was given 28 days later. Doses of AstraZeneca\u2019s vaccine were scheduled 4-to-12 weeks apart across four trials.<\/p>\n
Vaccines are intended to hardwire immunological memory to generate a rapid, targeted and durable response by antibodies and T-cells to an invading foe. Typically booster shots are intended to provide the immune system with advanced \u201ctraining\u201d to make better antibodies. Some vaccines requiring multiple doses are administered four months apart to optimize immune memory. Covid-19 vaccines may work the same way, but it will take additional patient studies to know this for sure. Johnson & Johnson is studying a single-shot Covid-19 vaccine, with results expected to be analyzed soon.<\/p>\n
By using shots that normally would have gone to people who have already received the first dose, countries including France and the U.K. are aiming to<\/span> give more people an initial dose. That followed a move by U.S. health authorities to revise guidance that recommended an interval of three or four weeks between doses of the Moderna and Pfizer-BioNTech vaccines. The new guidance said doses can be spaced out by up to<\/span> six weeks if it\u2019s impossible to get the follow-up shot on time. The FDA said slight delays shouldn\u2019t affect the protection offered by the vaccine.<\/p>\n It\u2019s hard to know without more research. Data from the Pfizer-BioNTech trial found partial protection was achieved as early as 12 days after the first dose, but two doses were required to provide maximum efficacy, or 95% protection against disease. There are no data to demonstrate that protection after the first dose is sustained after 21 days. There is also concern that inoculated patients may change their behavior in a way that increases the risk of spread, negating some of the benefits of vaccination. In a split with other regulators, the European Medicines Agency said that changing how coronavirus vaccines are given to people raises the risk of reducing effectiveness.<\/p>\n They\u2019re medical, theoretical, and social. The medical risk is that the first dose almost certainly won\u2019t be as protective as two doses. Spacing out doses extends the period when people — most of whom have been chosen to get vaccines quickly at this point for reasons of vulnerability — will have incomplete protection until they get their second dose. The theoretical risk is that a weak response to the virus in millions of people who have received just one dose would foster the emergence of new variants that could evade vaccine-induced antibodies. This would undermine a year\u2019s work to develop safe and effective vaccines. And the social risk is that mixed messages on the topic — from governments, regulators, professional groups and drugmakers — will make it more difficult to communicate with the public on vaccines that are already controversial, and shunned by some.<\/p>\n By late January, Israel had given more than a quarter of its people at least one dose. Health officials there have noted<\/span> that cases started to decline within two weeks of the shots being administered, and before people began receiving a second dose. However, some data collected from older residents vulnerable to developing severe illness indicated the first dose led to a 33% reduction in Covid-19 cases, far lower than the effectiveness after two doses. Data collected by AstraZeneca, however, shows that pacing out doses by 8-12 weeks may actually be the efficacy \u201csweet spot,\u201d Mene Pangalos, the drugmaker\u2019s executive vice president for biopharmaceutical research and development, told a U.K. government panel. The U.K. drugs regulator has recommended the AstraZeneca vaccine be administered within an interval of up to<\/span> 12 weeks. The World Health Organization says that, although there is some data to support that interval for the AstraZeneca vaccine, there is no scientific evidence to stretch the second dose of the Pfizer-BioNTech vaccine to 12 weeks.<\/p>\n Although AstraZeneca has been in favor of spacing out shots, Moderna and Pfizer have been more cautious. Pfizer said the safety and efficacy of its vaccine hasn\u2019t been evaluated on different dosing schedules, and that it\u2019s critical health authorities carefully monitor the effects of any alternative regimens and ensure each recipient is afforded the maximum possible protection, \u201cwhich means immunization with two doses of the vaccine.\u201d Anthony Fauci, the American infectious-diseases doctor who heads the National Institute of Allergy and Infectious Diseases, has said he wouldn\u2019t be in favor of stretching the dosing schedule. The British Medical Association has gone further, calling for the U.K. to \u201curgently review\u201d its decision to allow delays of the Pfizer-BioNTech vaccine. The U.K. physicians group supports delays of up to<\/span> six weeks, but said Britain\u2019s plan goes \u201cwell beyond\u201d that.<\/p>\n3. What will the delay do?<\/h3>\n
4. What are the risks of spacing out doses?<\/h3>\n
5. What\u2019s happened in countries with rapid vaccination?<\/h3>\n
6. What do others say?<\/h3>\n
The Reference Shelf<\/h3>\n
\n